Top of this page
Skip navigation, go straight to the content
UCB is a global biopharmaceutical company focused on creating value for people living with severe diseases in immunology and neurology.
We work with stakeholders to address the unmet needs of patients and caregivers, helping them to achieve their goals and to live the lives they want. UCB is on a journey to become the patient-preferred biopharma leader by delivering medicines and solutions that improve lives. Our commitment to value is a promise to bring together the talent, expertise, tools and scientific know-how required to serve patients in need.
UCBCares: Providing Dedicated Patient Support
Clinical studies at UCB: How are medicines made and tested?
At UCB, we take our responsibility
to the planet very seriously.
UCB Ventures, our strategic corporate venture fund established in 2017
Twitter Feed
-
#Antibodies could help combat #neurodegenerativediseases, even potentially halt brain cell degeneration. Take a peek at our research: https://t.co/CCqlMycwJG https://t.co/BEUCHKlzhz
— UCB News (@ucb_news) 13.11.2019 -
Patients with non-radiographic axial spondyloarthritis report substantial impairment in household productivity and daily activities due to disease burden. We are committed to raising the standard of care for people living with chronic #rheumatic diseases.
— UCB News (@ucb_news) 13.11.2019 -
#DYK #atopicdermatitis & #psoriasis affect 300 million people worldwide. Read how @BIOMAP-IMI hopes to pave the way for a more individualized approach to therapy. https://t.co/L4ZRU7hbBK #InspiredByPatients #DrivenByScience https://t.co/NIjY5ry4u3
— UCB News (@ucb_news) 12.11.2019
